Question 1

What is Viatris's EV/EBITDA ratio?

Accepted Answer

Viatris (VTRS) EV/EBITDA ratio is 16.5× as of June 5, 2026. The ratio is calculated by dividing enterprise value by trailing twelve-month EBITDA, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the EV/EBITDA ratio calculated?

Accepted Answer

EV/EBITDA = Enterprise Value ÷ Trailing Twelve-Month (TTM) EBITDA, where Enterprise Value = Market Capitalisation + Total Debt − Cash & Short-Term Investments. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the EV/EBITDA ratio?

Accepted Answer

The EV/EBITDA ratio (the enterprise multiple) compares enterprise value (EV) to trailing twelve-month (TTM) EBITDA. EV is calculated as market capitalisation + total debt − cash & short-term investments. Because EV/EBITDA is capital-structure-neutral and ignores non-cash depreciation and amortisation, it is the standard multiple used in M&A and for cross-company or cross-border comparisons. Note: this calculation uses a simplified EV (minority interest and preferred equity excluded due to data availability), consistent with most public financial-data providers.

Question 4

What is a good EV/EBITDA ratio for Viatris?

Accepted Answer

Mature, cash-generative businesses commonly trade in the 8–12× EV/EBITDA range; higher-growth, asset-light companies often trade at 15–25×+. EV/EBITDA is most useful for comparing companies with different capital structures (debt levels) or tax regimes. For Viatris specifically, the relevant sector benchmark is the current sector median of 15.0×.

Question 5

Is Viatris's EV/EBITDA ratio high or low?

Accepted Answer

Viatris's EV/EBITDA ratio of 16.5× is above its own 5-year average of 8.5× and above the sector median of 15.0×. That places the current reading at the 98th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Viatris's historical EV/EBITDA ratio range?

Accepted Answer

In the available daily series, Viatris (VTRS) EV/EBITDA ratio has ranged from a low of 4.5× in 2023 to a high of 21.7× in 2015. The 5-year average is 8.5× and the 5-year median is 8.6×.

Question 7

What was Viatris's EV/EBITDA ratio in 2024?

Accepted Answer

Viatris (VTRS) EV/EBITDA ratio at the end of 2024 was 10.0×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month EBITDA figure available at that date.

Question 8

Why does Viatris's EV/EBITDA ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (enterprise value, which tracks share price plus net debt) and the denominator (EBITDA). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$14.35B	−$395.40M	—	—	Dec 31, 2025
2024	$14.86B	$2.82B	10.0×	+1.4×	Dec 31, 2024
2023	$13.00B	$3.52B	8.6×	+3.7×	Dec 31, 2023
2022	$13.59B	$6.43B	4.9×	-3.7×	Dec 31, 2022
2021	$16.22B	$4.48B	8.6×	-12.0×	Dec 31, 2021
2020	$16.01B	$1.99B	20.6×	+12.2×	Dec 31, 2020
2019	$10.37B	$2.69B	8.4×	-0.9×	Dec 31, 2019
2018	$14.10B	$2.95B	9.3×	-2.0×	Dec 30, 2018
2017	$22.56B	$3.24B	11.3×	-5.2×	Dec 30, 2017
2016	$20.47B	$2.10B	16.6×	+1.9×	Dec 30, 2016
2015	$27.56B	$2.29B	14.7×	-1.5×	Dec 30, 2015
2014	$22.17B	$1.87B	16.2×	—	Dec 30, 2014


Gilead Sciences (GILD)	13.9×
Labcorp Holdings (LH)	13.6×
Amgen (AMGN)	13.6×
Charles River (CRL)	13.2×
Regeneron Pharmaceuticals (REGN)	12.9×
GE HealthCare (GEHC)	12.9×
UnitedHealth Group (UNH)	12.7×
Pfizer (PFE)	12.4×
Henry Schein (HSIC)	12.0×
Medtronic (MDT)	11.7×
AptarGroup (ATR)	11.5×
Bristol-Myers Squibb (BMY)	11.5×
Zimmer Biomet Holdings (ZBH)	11.2×
Biogen (BIIB)	10.5×
HCA Healthcare (HCA)	10.0×
Molina Healthcare (MOH)	8.8×
DaVita (DVA)	8.5×
IQVIA (IQV)	8.2×
Incyte (INCY)	7.9×
Cigna (CI)	7.8×
Elevance Health (ELV)	6.8×
Novo Nordisk (NVO)	6.5×
Solventum (SOLV)	5.8×
Universal Health Services (UHS)	5.7×
Humana (HUM)	4.5×

EV/EBITDA for Viatris (VTRS)

EV/EBITDA daily chart for Viatris (VTRS)

Historical EV/EBITDA for Viatris (VTRS) from 2014 to 2025

About EV/EBITDA at Viatris (VTRS)

Viatris EV/EBITDA by Year

Viatris EV/EBITDA 2024: 10.0×

Viatris EV/EBITDA 2023: 8.6×

Viatris EV/EBITDA 2022: 4.9×

Viatris EV/EBITDA 2021: 8.6×

Viatris EV/EBITDA 2020: 20.6×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

Viatris (VTRS) Key Financials

EV/EBITDA daily chart for Viatris (VTRS)

Historical EV/EBITDA for Viatris (VTRS) from 2014 to 2025

About EV/EBITDA at Viatris (VTRS)

Viatris EV/EBITDA by Year

Viatris EV/EBITDA 2024: 10.0×

Viatris EV/EBITDA 2023: 8.6×

Viatris EV/EBITDA 2022: 4.9×

Viatris EV/EBITDA 2021: 8.6×

Viatris EV/EBITDA 2020: 20.6×

Sector peers by EV/EBITDA — chart

Sector peers by EV/EBITDA — table

Frequently asked questions

+What is Viatris's EV/EBITDA ratio?

+How is the EV/EBITDA ratio calculated?

+What is the EV/EBITDA ratio?

+What is a good EV/EBITDA ratio for Viatris?

+Is Viatris's EV/EBITDA ratio high or low?

+What is Viatris's historical EV/EBITDA ratio range?

+What was Viatris's EV/EBITDA ratio in 2024?

+Why does Viatris's EV/EBITDA ratio change over time?

Viatris (VTRS) Key Financials